UB Paderborn / Katalog / Suche / in CDI

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2

Journal of clinical oncology, 2016-02, Vol.34 (5), p.419-426

2016

Volltextzugriff (PDF)

Everolimus in hormone receptor–positive advanced breast cancer: Targeting receptor-based mechanisms of resistance

Breast (Edinburgh), 2013-08, Vol.22 (4), p.405-410

Shtivelband, Mikhail I

2013

Volltextzugriff (PDF)

A Fully Human Antimelanoma Cellular Adhesion Molecule/MUC18 Antibody Inhibits Spontaneous Pulmonary Metastasis of Osteosarcoma Cells In Vivo

Clinical cancer research, 2003-12, Vol.9 (17), p.6560-6566

2003

Volltextzugriff (PDF)

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2020-08, Vol.38 (22), p.2530-2542

2020

Volltextzugriff (PDF)

Advanced desmoplastic small round cell tumor: near complete response with trastuzumab-based chemotherapy

Clinical advances in hematology & oncology, 2009-07, Vol.7 (7), p.473-475

2009

Volltextzugriff (PDF)

Abstract P1-08-18: Impact of gene expression profile testing for lymph node positive (LN+) , hormone receptor positive (HR+), HER2 negative (HER2-) breast cancer (BC) patients on the use of adjuvant chemotherapy in a large community cancer center

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-08-18

2022

Volltextzugriff (PDF)

Phase 3 study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG3515)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS8607-TPS8607

2023

Volltextzugriff (PDF)

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

The Lancet. Haematology, 2019-09, Vol.6 (9), p.e459-e469

2019

Volltextzugriff (PDF)

Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab

Leukemia & lymphoma, 2021-05, Vol.62 (6), p.1353-1360

2021

Volltextzugriff (PDF)

Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9047-9047

2018

Volltextzugriff (PDF)

Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma after Prior Rituximab

Blood, 2017-12, Vol.130, p.1500-1500

2017

Volltextzugriff (PDF)

Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8022-8022

2020

Volltextzugriff (PDF)

A phase III study of MEDI4736 (M), an anti-PD-L1 antibody, in monotherapy or in combination with Tremelimumab (T), versus standard of care (SOC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who have received at least two prior systemic treatment regimens (ARCTIC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS8104-TPS8104

2015

Volltextzugriff (PDF)

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study

European journal of cancer (1990), 2013-08, Vol.49 (12), p.2621-2632

2013

Volltextzugriff (PDF)

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial

The Lancet. Haematology, 2021-04, Vol.8 (4), p.e254-e266

2021

Volltextzugriff (PDF)

Maintenance of health-related quality of life in elderly patients treated with ribociclib + letrozole in MONALEESA-2

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1041-1041

2018

Volltextzugriff (PDF)

Purification and characterization of a cyclooxygenase‐2 and angiogenesis suppressing factor produced by human fibroblasts

The FASEB journal, 2002-08, Vol.16 (10), p.1286-1288

2002

Volltextzugriff (PDF)

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer

Journal of clinical oncology, 2015-02, Vol.33 (5), p.433-441

2015

Volltextzugriff (PDF)

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study

Clinical breast cancer, 2019-08, Vol.19 (4), p.268-277.e1

2019

Volltextzugriff (PDF)

Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non–Small-Cell Lung Cancer

Clinical lung cancer, 2016-05, Vol.17 (3), p.169-176

2016

Volltextzugriff (PDF)

Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.7504-7504

2017

Volltextzugriff (PDF)

A prospective registry study assessing decision impact and patient outcomes following gene-expression profiling for tumor-site origin

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e22172-e22172

2013

Volltextzugriff (PDF)

Weekly nab -paclitaxel ( nab -P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS1106-TPS1106

2015

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2

Everolimus in hormone receptor–positive advanced breast cancer: Targeting receptor-based mechanisms of resistance

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

A Fully Human Antimelanoma Cellular Adhesion Molecule/MUC18 Antibody Inhibits Spontaneous Pulmonary Metastasis of Osteosarcoma Cells In Vivo

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer

Advanced desmoplastic small round cell tumor: near complete response with trastuzumab-based chemotherapy

Abstract P1-08-18: Impact of gene expression profile testing for lymph node positive (LN+) , hormone receptor positive (HR+), HER2 negative (HER2-) breast cancer (BC) patients on the use of adjuvant chemotherapy in a large community cancer center

Phase 3 study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG3515)

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab

Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC)

Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma after Prior Rituximab

Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study

A phase III study of MEDI4736 (M), an anti-PD-L1 antibody, in monotherapy or in combination with Tremelimumab (T), versus standard of care (SOC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who have received at least two prior systemic treatment regimens (ARCTIC)

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial

Maintenance of health-related quality of life in elderly patients treated with ribociclib + letrozole in MONALEESA-2

Purification and characterization of a cyclooxygenase‐2 and angiogenesis suppressing factor produced by human fibroblasts

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study

Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non–Small-Cell Lung Cancer

Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study

A prospective registry study assessing decision impact and patient outcomes following gene-expression profiling for tumor-site origin

Weekly nab -paclitaxel ( nab -P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity)

Suchergebnisse filtern